[HTML][HTML] Interim guidelines on antiviral therapy for COVID-19

SB Kim, K Huh, JY Heo, EJ Joo, YJ Kim… - Infection & …, 2020 - ncbi.nlm.nih.gov
Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019,
Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January …

Treating COVID-19: are we missing out the window of opportunity?

J Sundararaj Stanleyraj, N Sethuraman… - Journal of …, 2021 - academic.oup.com
Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a
cascade of inflammatory events. Progression to severe disease is predominantly a function …

Anti COVID-19 drugs: need for more clinical evidence and global action

Z Khan, Y Karataş, H Rahman - Advances in therapy, 2020 - Springer
Abstract The World Health Organization (WHO) called the outbreak of coronavirus infectious
disease-2019 (COVID-19) a “Public Health Emergency of International Concern”(PHEIC) …

[PDF][PDF] COVID-19: interim guidance on management pending empirical evidence

KC Wilson, SH Chotirmall, C Bai, J Rello - From an American thoracic …, 2020 - persi.or.id
COVID‐19: Interim Guidance on Management Pending Empirical Evidence. From an American
Thoracic Society‐led Int Page 1 1 Updated April 3, 2020 COVID‐19: Interim Guidance on …

[HTML][HTML] COVID19-clinical presentation and therapeutic considerations

G Kenny, PW Mallon - Biochemical and biophysical research …, 2021 - Elsevier
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a
pandemic infection in 2020 has presented many therapeutic challenges. Not least among …

[HTML][HTML] Fármacos prometedores y potenciales para el tratamiento de COVID-19

C Moneriz, C Castro-Salguedo - Revista chilena de infectología, 2020 - SciELO Chile
La enfermedad por coronavirus 2019 (COVID-19) se caracteriza por cuadros respiratorios
de sintomatología variada, que puede cursar desde manifestaciones leves, hasta cuadros …